Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
27 janv. 2023 09h00 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and fully integrated gene therapy company dedicated to challenging the...
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
12 déc. 2022 12h00 HE
|
Spark Therapeutics, Inc.
Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and infusion ratesData shared during...
Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor
23 févr. 2022 10h29 HE
|
Spark Therapeutics, Inc.
Under Jeff Marrazzo’s leadership, Spark launched world’s first FDA-approved gene therapy for a genetic disease. He also spearheaded Spark’s $4.8 billion acquisition by Roche. Company’s...
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
17 déc. 2021 08h00 HE
|
Spark Therapeutics, Inc.
Roche affirms its long-term commitment to Philadelphia as gene therapy center of excellence Spark signs 99-year ground lease of Drexel University’s property, to create a premier environment for...
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients
17 nov. 2021 17h01 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01
12 oct. 2021 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date
21 juil. 2021 10h12 HE
|
Spark Therapeutics, Inc.
Factor VIII (FVIII) expression was sustained in 16 of 18 participants with up to 4 years of follow-up to the administration of SPK-8011 Across all dose cohorts, there was a 91.2% reduction in...
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
13 avr. 2021 08h30 HE
|
Spark Therapeutics, Inc.
Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies...
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
25 févr. 2021 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
05 févr. 2021 10h51 HE
|
Spark Therapeutics, Inc.
Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X1011 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable...